Embecta (EMBC)
Sells pen needles, syringes, and newer drug-delivery devices for diabetes and chronic care.
$5.53
vs last close+0.23 (+4.25%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 90.83% | 51.46M shares | |
|---|---|---|---|
| 326 holders · as of Jun 30, 2026 | |||
| Insiders | 3.87% | 2.19M shares | |
| 14 holders · as of Sep 8, 2026 | |||
| Other | 5.30% | 3.00M shares | |
| remainder | |||
56.66M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
326 holders · 51.46M shares · 66 new positions · 144 increased · 75 reduced · 82 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.60M | 8.12% | −4.57M | Aug 7, 2026 |
| Yacktman Asset Management LP | 4.32M | 7.62% | +644.1K | Aug 11, 2026 |
| Vanguard Capital Management LLC | 2.56M | 4.51% | −6.8K | Aug 13, 2026 |
| Deerfield Management Company, L.P. (Series C) | 2.53M | 4.47% | 0 | Aug 14, 2026 |
| Jefferies Financial Group Inc. | 2.36M | 4.16% | −45 | Aug 17, 2026 |
| Ameriprise Financial Inc | 2.04M | 3.60% | +1.24M | Aug 14, 2026 |
| Morgan Stanley | 2.00M | 3.52% | +1.39M | Aug 13, 2026 |
| State Street Corp | 1.61M | 2.84% | −935.3K | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 15.00% | 8.75M | 13G | Jul 18, 2025 |
| Yacktman Asset Management LPincl. Amg Yacktman Fund | 6.20% | 3.67M | 13G | May 5, 2026 |
| Stowers Institute for Medical Researchincl. American Century Investment Management, Inc., American Century Capital Portfolios, Inc. +1 more | 5.80% | 3.44M | 13G | May 1, 2026 |
| Vanguard Capital Management | 5.07% | 3.00M | 13G | Apr 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 4, 2026 | Milton Mayo Morrisdirector | Sale | 6,293 | $5.88 | 53,828 |
| Aug 12, 2026 | Jacob Elguiczeofficer: SVP and CFO | Purchase | 20,000 | $4.67 | 309,139 |
| Aug 12, 2026 | Devdatt Kurdikardirector, officer: President and CEO | Purchase | 30,000 | $4.70 | 804,919 |
| Aug 12, 2026 | Robert J. Hombachdirector | Purchase | 45,000 | $4.97 | 109,587 |
| Aug 12, 2026 | Jeffrey Z. Mannofficer: Pres, Pharm Svc&Prod Mgmt, CLO | Purchase | 20,000 | $4.99 | 262,915 |
House and Senate disclosures
Not reported.